Plasma-derived drugs are among the most complex medicines in existence. Made from human blood plasma, they provide therapies for immune deficiencies, bleeding disorders, autoimmune conditions, and rare genetic diseases — often when no alternative exists. For patients with hemophilia, primary immunodeficiency, or hereditary angioedema, plasma-derived therapies are not optional; they are essential. As diagnosis improves and access expands, the plasma-derived drugs market continues to grow.

The plasma-derived drugs market includes immunoglobulins, coagulation factors, albumin, protease inhibitors, and other plasma protein therapies. Growth is driven by rising diagnosis of rare diseases, expanded access in emerging markets, and increasing demand for immunoglobulin therapies in neurology and immunology.

What Are Plasma-Derived Drugs?

Plasma is the liquid portion of blood, rich in proteins that perform critical functions — clotting, immune defense, and fluid balance. Plasma-derived drugs are manufactured by fractionating donated plasma to isolate specific proteins, which are then purified and formulated into therapies.

Key Product Categories

• Immunoglobulins (IVIG and SCIG): immune deficiencies and autoimmune conditions

• Coagulation factors: hemophilia A and B

• Albumin: volume expansion and liver disease support

• Protease inhibitors: hereditary angioedema

• Fibrinogen and other proteins: specialized clotting disorders

People Also Ask

What are plasma-derived drugs used for?
They treat immune deficiencies, bleeding disorders like hemophilia, autoimmune conditions, hereditary angioedema, and other rare diseases — often as lifelong replacement therapies.

How are plasma-derived drugs made?
They are manufactured by separating and purifying specific proteins from donated human plasma through a process called fractionation, followed by viral inactivation and rigorous quality testing.

The Human Dimension

Plasma-derived drugs depend entirely on plasma donations. Maintaining an adequate donor base is a persistent challenge, particularly in regions where donation infrastructure is limited. This supply constraint is one of the defining features of the market — and a key reason manufacturers invest heavily in plasma collection networks.

Tags: #PlasmaDerivedDrugs #Immunoglobulins #Hemophilia #PlasmaTherapies #RareDiseases #Biopharmaceuticals #PlasmaDonation